Business Context and Reporting Period
This Form 8-K filing by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) was filed on August 6, 2018, reporting events occurring on August 2, 2018. The company is a Delaware corporation focused on developing therapies for autoimmune, inflammatory, and pain conditions.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance changes.
Material Changes
The primary material change is the appointment of Christopher Posner to the Board of Directors to fill the vacancy left by the resignation of Dean Slagel. Mr. Posner was also appointed to the Audit Committee and the Compensation Committee.
Management Commentary and Compensation
Mr. Posner brings extensive experience in commercial operations from LEO Pharma, R-Pharma, Bristol-Myers Squibb, Pfizer, and others. His compensation package includes:
- Annual cash retainer of $40,000 for director service.
- Additional annual retainer of $10,000 for Audit Committee service.
- Additional annual retainer of $7,500 for Compensation Committee service.
- Initial option grant to purchase 35,000 common shares at an exercise price of $17.94, vesting over three years.
The Board also reconstituted its standing committees effective August 2, 2018.
Investor Verification Checklist
- Verify the resignation details of former director Dean Slagel.
- Confirm the vesting schedule and exercise price of the 35,000 stock options granted to Mr. Posner.
- Review the updated composition of the Audit, Compensation, and Nominating committees.
- Check for any subsequent filings regarding the indemnification agreement for Mr. Posner.